Newsletter | July 24, 2019

07.24.19 -- Machine Learning In Clinical Trials: What Will The Future Hold?

  CRO Quality Benchmarking: Phase 1 Service Providers (11th Edition)

This market research report is available for purchase below. Its goal is to provide detailed information to aid in making informed decisions when outsourcing Phase 1 work. You can purchase a single-user license for individual use, a site-wide license giving access to the report for all employees within a single site/office location, or an enterprisewide license giving access to all employees within your organization.

Featured Editorial
Machine Learning In Clinical Trials: What Will The Future Hold (And What’s Holding Us Back)?
By Kellie Rademacher, Pharm.D., Precision for Value

While the industry is taking baby steps into using machine learning in clinical trials and for other data-generating objectives, the value of this data will depend on the transparency of algorithms, robustness of data sources, and extrapolation to real-world outcomes.

Industry Insights
Next-Gen Bioinformatics: The Expanding Role Of Deep-Learning Algorithms
Article | By Jen Brown, Thermo Fisher Scientific

Deep-learning algorithms have shown significant promise as applications in natural language understanding, decision making, and speech and image recognition. These algorithms are now being applied in bioinformatics applications within the biopharma industry to manage the increasing amounts of data from high-throughput techniques. Read more about recent applications of these algorithms to predict a variety of biological processes and interactions, particularly with respect to proteins.

2019 Unified Clinical Operations Survey Report
Article | Veeva Systems, Inc.

See new results from one of the industry's largest global clinical operations surveys. Findings show sponsors and CROs are making progress in unifying clinical systems, streamlining end-to-end processes, and aligning stakeholders to improve trial performance.

Industry Perceptions And Expectations: The Role Of ICER As An Independent HTA Organization
White Paper | ICON Plc

In this paper, ICER’s influence over the payer and manufacturer spheres is evaluated through primary research with two groups of stakeholders. A secondary budget impact analysis was also conducted in order to estimate the potential savings to the U.S. healthcare system if ICER’s cost-effective prices were implemented across a selection of therapeutic areas.

The Big Picture: Impact Of EU Disclosure On Small And Midsize Sponsors
Webinar | TrialScope
With the new EU clinical trial registry portal expected to launch next year, it is imperative that sponsors — particularly small and midsize organizations — understand the complexities of EU disclosure. Thomas Wicks, an expert in clinical trial disclosure, and Karen Rutkowski, an expert in medical writing, share actionable insights on compliance.

The 9th Annual DPharm: Disruptive Innovations to Advance Clinical Trials welcomes Dr. Scott Gottlieb, twenty-third commissioner of the FDA, to deliver an industry keynote with his views on modernizing clinical trials. More than 20 pharma companies are reporting on specific innovations they have developed to better deliver new medicines, covering the full spectrum of clinical research. Taking place September 17 and 18, 2019, in Boston, MA. Use code LSL15 for 15% off.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.

Connect With Clinical Leader: